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Abstract: Background: Computed tomography enterography (CTE) is a useful modality in the evaluation of small bowel 
(SB) crohn`s disease (CD) as it can provide assessment of disease activity, extramural abnormalities and SB 
complications. This procedure however utilises radiation exposure. The aim of this retrospective study was to determine 
the clinical indications and findings on CTE and to determine if serum bio-markers (CRP, ESR, platelet count and 
anaemia) can predict significant pathologies.  
Method: This was a retrospective analysis where 50 patients above the age of 18 with CD who had CTE between 
October 2013 and February 2015 were identified. The clinical indications, serum bio-markers and CTE findings in these 
patients were analysed.  
Results: The main indications for CTE were abdominal pain/discomfort and/or symptoms suggestive of SB obstruction. 
26% of CD patients had active inflammation, 36% had a SB stricture and 4% had active inflammation with stricturing and 
fistulating disease. All the patients with a completely normal CTE did not have a raised bio-marker whist 76.9% of 
patients with active inflammation had one or more positive bio-markers. Additional findings were active colitis (8%), 
splenomegaly (4%), aortitis (2%) and had sacroileitis (2%). In these patients, 75% had a positive bio-marker. In patients 
with positive findings, the Erythrocyte Sedimentation Rate (ESR) was the most common marker of inflammation.  
Conclusion: CTE is an important tool in management of patients with CD however, in the presence of normal 
biomarkers, clinicians should question the need for CTE and thus decrease exposure of CD patients to ionising radiation.  
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INTRODUCTION 
Crohn’s disease (CD) is characterized by a chronic, 
focal, discontinuous granulomatous transmural 
inflammation. Management of CD requires assessment 
of the location, extent, activity and severity of 
inflammatory lesions and of any potential complications 
[1]. A diagnosis is usually obtained through histological 
analysis of biopsies taken during endoscopy [2]. 
However, further radiological imaging, particularly of 
the small bowel (SB), may be required. This usually 
takes the form of cross sectional imaging since the 
length of the SB makes it cumbersome to perform a 
panenteroscopy on all patients with suspected SB 
disease. Capsule endoscopy (CE) can be used to 
assess and screen the SB for CD related pathology. 
However, the risk of capsule retention in patients with 
CD is 5-13% [3].
 
SB assessment can also be done through 
computed tomography enterography (CTE) [4]. The 
technique of CTE is a combination of small bowel 
distension using a neutral or low-density oral contrast 
mixture with an abdomino-pelvic CT (computed 




Address correspondence to this author at the Department of Medicine, 2nd 
Floor, Brown Block, Mater Dei Hospital, Msida, MSD 2090, Malta;  
E-mail: anthea.brincat@gov.mt 
following administration of intravenous contrast [5]. The 
advantages of CTE are that it can be easily performed, 
is well tolerated by patients, allows comparison with 
previous cross-sectional imaging, is operator-indepen- 
dent and allows simultaneous assessment for extra-
luminal manifestations. This makes it one of the 
investigations of choice in cases of suspected SB 
stricture [5, 6]. In established disease, CTE can help in 
selecting treatment and assessing response [1]. It is, 
however, less sensitive than CE in detecting early 
mucosal abnormalities and it utilises ionising radiation 
[5].
 
In CD, CTE may identify active inflammation, 
fibrostenosing disease and complications such as 
fistulae or abscesses. Features of active inflammation 
include mural hyperenhancement, mural thickening and 
stratification, transmural ulceration, engorged vasa 
recta and increased attenuation of mesenteric fat [6, 7]. 
A study on resected pathological specimens of patients 
with CD showed a good correlation between findings 
suggestive of inflammation or fibrostenosing disease 
seen on CTE and inflammatory changes seen in the 
pathological specimens [8]. 
The major drawback with CTE is that it requires 
exposure to ionising radiation. Patients with CD are 
relatively young and may undergo repeated 
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investigations due to the chronic, relapsing nature of 
CD. It is estimated that 1.5-2% of all cancers in the 
USA may be caused by radiation exposure [9].
 
CT 
accounts for 16.2% of imaging studies in patients with 
CD and for 77.2% of diagnostic radiation [10]. Another 
study showed that CT exposures were estimated to 
produce 0.7% of total expected baseline cancer 
incidence and 1% of total cancer mortality [11]. Other 
drawbacks include the potential contrast toxicity and 
the need to drink large volumes of fluid over a short 
period of time so as to achieve luminal distension. 
Laboratory blood investigations can be associated 
with active CD. The most common changes in the 
complete blood count related to CD are anaemia and 
thrombocytosis [2]. Anaemia has been associated with 
active CD however its aetiology can be multifactorial 
(iron, folate or Vitamin B12 deficiency, myelo- 
suppression, haemolysis and inflammation) [12]. C 
Reactive Protein (CRP) and Erythrocyte Sedimentation 
Rate (ESR) are other markers of inflammation. CRP is 
the most studied inflammatory marker and correlates 
well with disease activity, with a sensitivity of 70-100%. 
It has a short half-life (about 19 hours) and thus rises 
early after the onset of inflammation and rapidly 
declines after resolution of the inflammation [13]. 
Studies have shown that when correlating CRP with 
CTE findings, CRP correlates mostly with increased 
attenuation of mesenteric fat [14]. ESR is the rate at 
which erythrocytes sediment over one hour and so will 
be higher in inflammation due to a slower rate. It 
reaches a peak less rapidly and declines over several 
days, even if the inflammation has ameliorated [15]. 
ESR correlates better with colonic, rather than ileal, 
disease [15]. 
However, (1) in the absence of an ideal bio-marker 
for active CD, (2) the presence of symptoms in patients 
with CD which could be due to the disease itself or 
other gastrointestinal pathology and (3) the availability 
and reliability of CTE, the latter test is very often 
requested. The aim of this retrospective study were (1) 
to analyse the indications and findings on CTE (2) and 
to correlate the findings on CTE with blood biochemical 
bio-markers (CRP, ESR, haemoglobin and platelets) as 
to positively identify which patients would benefit 
mostly from this tests as to decrease their radiation 
exposure.  
METHOD 
This was a retrospective analysis where 50 patients 
above the age of 18 with CD who had CTE between 
October 2013 and February 2015 were identified 
through the Medical Imaging department. The clinical 
indications, serum biochemical markers and CTE 
findings in these patients were analysed. Active 
inflammation was deemed to be present if one or more 
of the following were present: wall thickening, mural 
hyperenhancement, enlarged lymph nodes and 
increased vascularity. All the CTE were interpreted by 
the same radiologist.  
The chosen blood bio-markers were haemoglobin, 
platelet count, ESR and CRP. Anaemia was 
considered to be present at haemoglobin levels of less 
than 11.5g/dL in females and less than 13g/dL in 
males, as these are the lower limit of the laboratory 
range at our laboratory. The cut-off for the platelet 
count was 400x10
9
/L. The CRP was considered to be 
positive if it was more than 6mg/L. The cut-off value for 
the ESR depended on the patient’s gender and age 
[16]. The presence of anaemia, raised platelet count, 
ESR and CRP were considered as positive bio-
markers. 
RESULTS 
Radiological Studies  
Fifty CTE studies of CD patients were identified and 
analysed. Their mean age was 43.5 years (18-75 
years). Fifty-eight per cent (58%) of patients were 
female. The main indications for CTE were (1) to 
assess and determine the extent and degree of SB 
involvement due to persistent gastrointestinal 
symptoms which were clinically suggestive of SB 
pathology (68%), (2) to assess for small bowel 
obstruction in CD patients with signs and/or symptoms 
suggestive of obstruction (22%), (3) intestinal biopsies 
suggestive of but not conclusive for CD (8%) and (4) to 
assess extent of SB inflammation prior to commencing 
anti-tumour necrosis factor alpha treatment (2%). 
SB pathology was present in 66% of patients. Active 
SB inflammation was present in 26%, a SB stricture 
was present in 36% and 4% had active inflammation 
with associated SB stricturing and fistulating disease. 
Two patients with an inflammatory stricture developed 
small bowel obstruction. 
No small bowel pathology was present in 34% of 
patients. However within this group of patients there 
were other significant findings. These were active 
colitis (8% of total), splenomegaly (4% of total), aortitis 
(2% of total) and sacroileitis (2% of total). 
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Serum Bio-markers 
The serum bio-markers (haemoglobin, platelet 
count, ESR and CRP) were analysed for all the 
patients and compared to the radiological findings. 
Figure 1 best depicts the correlation between the 
radiological findings and serum bio-markers. The 
majority (76.9%) of patients with active inflammation 
had one or more positive bio-markers, this being 75% 
for patients with stricturing or fistulating disease. All the 
patients with a completely normal CTE did not have a 
raised bio-marker. 75% of patients with an additional 
finding (colitis, splenomegaly, aoritis or sacroileitis) had 
a positive bio-marker. Table 1 demonstrates the 
positive and negative predictive values for each serum 
bio-marker. 
In patients with positive findings, the ESR was the 
most common marker of inflammation. It was elevated 
in 69.2% of patients with active inflammation and 60% 
of patients with stricturing or fistulating disease. It was 
raised in 75% of patients with other intra-abdominal 
findings and was not raised in any patient with a 
completely normal CTE. The CRP was positive in 
38.5% of patients with active inflammation, in 50% of 
those with stricturing and fistulating disease and in 
37.5% of patients with additional intra-abdominal 
findings. Anaemia was present in 30.8% of those with 
active inflammation, 45% of those with stricturing and 
fistulating disease and 25% of those with additional 
intra-abdominal findings. Thrombocytosis was present 
in 23.3% of patients with active inflammation, 20% of 
patients with stricturing and fistulating disease and 25% 
of patients with additional intra-abdominal findings. 
 
Figure 1: A graph demonstrating the number of positive bio-markers of inflammation (0, 1, 2 or 3 or more) and the CTE findings. 
SB- small bowel. 
 
Table 1: A Table Showing the Positive and Negative Predictive Values for Small Bowel Pathology for Each of the 
Biomarkers Investigated 
Serum Bio-Marker Predictive Value Percentage 
Erythrocyte sedimentation rate PPV for SB pathology 100% 
 NPV for SB pathology 43% 
C-Reactive Protein PPV for SB pathology 100% 
 NPV for SB pathology 33% 
Anaemia PPV for SB pathology 100% 
 NPV for SB pathology 30% 
Thrombocytosis PPV for SB pathology 100% 
 NPV for SB pathology 26% 
PPV – Positive Predictive Value; NPV – negative predictive value, SB – small bowel 
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None of the patients with a completely normal CTE had 
a positive bio-marker.  
DISCUSSION 
CTE is useful in assessing for active inflammation, 
fibrostenosing disease and complications associated 
with CD such as fistulae or abscesses. Its use is limited 
by patient exposure to ionizing radiation. The majority 
(76.9%) of patients who had active inflammation in our 
study group had one or more raised inflammatory 
markers. 75% of patients with stricturing and/or 
fistulating disease had one or more positive markers. 
Most of the patients in the study group were relatively 
young. Clinicians must consider the cumulative 
radiation dose when selecting investigations. When 
possible, dose reduction techniques should be applied 
in CTE image acquisition protocol [6]. Other imaging 
investigations that are of value in CD include 
ultrasonography, magnetic resonance enterography 
(MRE), nuclear medicine techniques such as white 
blood cell scintigraphy and CE. MRE provides cross-
sectional imaging with similar diagnostic accuracy to 
CTE without exposing the patient to ionising radiation 
[1]. Its main drawbacks are that it is usually less 
available, is more time-consuming and might not be 
accepted by claustrophobic patients.  
One of the limitations of this study could be the 
relatively small numbers of CD patients. However, we 
think that there was definitely an important outcome as 
we have demonstrated that all patients with a 
completely normal CTE had no positive blood bio-
marker identified. Another limitation of this 
retrospective study is the lack of the faecal bio-marker 
calprotecin. Being a retrospective study we did not 
have a faecal calprotectin (FC) for each patient. Only 
38% of patients had a FC. However, although the 
important role of FC in inflammatory bowel disease has 
been demonstrated, there are still some unanswered 
questions. The optimal cut-off value of FC which 
predicts remission is still to be determined as various 
studies report varies levels from 56-340mg/kg.[17,18] 
Other studies have demonstrated a limited role for FC 
in determining SB pathology [19, 20]. All this is also 
demonstrated by the FC in our study group. For 
patients with SB pathology (inflammation and 
inflammatory stricturing), 5.3% had an FC of < 
50mg/kg, 15.8% had an FC value between 50-
200mg/kg and in 36.8% the level was > 200mg/kg. For 
patients with no SB pathology, none had an FC level 
<50mg/kg. An elevated FC of between 50-200mg/kg 
was present in 26.3% of patients and 15.8% had a 
level of > 200mg/kg. This group of patients did not 
have any evidence of active colonic disease. 
CONCLUSION 
CTE is a valuable technique in detecting active and 
complicated small bowel CD. In CD patients, due to 
their young age and risk of radiation exposure, the 
presence of normal serum bio-markers should alert the 
clinician to question the real need for CTE. Other 
investigations such as capsule endoscopy with patency 
capsule and/or MRE should be considered as 
alternatives. 
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